Amanta Healthcare Limited · NSE:AMANTA
Amanta Healthcare — Q2 FY27 Earnings Presentation
36 slides from Amanta Healthcare's earnings presentation, Nov 4, 2026
Slide 1: Exchange filing cover letter
Registered & Corporate Office: AMANTA HEALTHCARE LIMITED 8th Floor, Shaligram Corporates, CJ Marg, Ambli, Ahmedabad–380058, Gujarat, INDIA. Tel.: 079 – 67777600 Email: info@amanta.co.in Website: www.amanta.co.in CIN: L24139GJ1994PLC023944 November 4, 2026 To, To, Sr. General Manager Sr. General Mana
Slide 2: Amanta Healthcare Limited Q2 & H1 FY27 Investor Presentation
Amanta Healthcare Limited Q2 & H1 FY27 Investor Presentation November, 2026
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Amanta Healthcare Ltd. (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securit
Slide 4: Performance
SECTION 01 Performance Q2 & H1 FY27 Financial Highlights The capacity-led growth phase begins
Slide 5: Strategic Highlights
Strategic Highlights Q2FY27 topline grows 17% with PAT growth of 26% YoY basis 01 Financial performance 02 SteriPort Line 3 is live • Q2 FY27 revenue ₹83.13 Cr, 17.3% YoY • Commissioned in the first week of September 2026 at the existing • Q2 FY27 EBITDA ₹17.95 Cr; margin 21.6%, resulting in PAT of
Slide 6: Financial Performance – Q2FY27
Financial Performance – Q2FY27 (Figures in INR Cr.) Revenue EBITDA and Margins (%) PAT and Margins (%) 83 18 5 15 71 1 21% 22% 2% 6% Q2FY26 Q2FY27 Q2FY26 Q2FY27 Q2FY26 Q2FY27 Revenue PAT and Margins (%) EBITDA and Margins (%) 83 18 69 15 5 3 22% 22% 5% 6% Q1FY27 Q2FY27 Q1FY27 Q2FY27 Q1FY27 Q2FY27 5
Slide 7: Profit and Loss Statement
Profit and Loss Statement (Figures in Rs. crs) Particulars Q2FY27 Q2FY26 YoY H1FY27 H1FY26 YOY Revenues 83 71 17% 152 136 12% Other Income 1 0 - 1 1 36% Total Income 84 71 18% 153 137 12% Cost of materials consumed 28 24 17% 50 48 6% Purchases of stock-in-trade 1 2 -38% 4 5 -18% Changes in inventori
Slide 8: Balance Sheet
Balance Sheet (Figures in Rs. crs) Assets FY26 H1FY27 Equities & Liabilities FY26 H1FY27 Non-Current Assets Equity share capital 39 39 Property, plant and equipment 197 312 Other Equity 181 189 Capital work-in-progress 82 0 Net Worth 220 228 Right-of-use assets 9 8 Intangible assets 1 1 Non-Current
Slide 9: Growth Levers
Growth Levers Three pillars working together towards 20%+ revenue CAGR and 25%+ EBITDA margin 01 MARKET DEPTH 02 MANUFACTURING 03 EFFICIENCY Wallet share expansion Capacity expansion Green energy & cost optimisation • Complex dosages and niche molecules across • SteriPort Line 3 live since Sep 2026:
Slide 10: Company Overview
SECTION 04 Company Overview Amanta at a Glance IN THIS SECTION Business model Product portfolio Manufacturing & technology Exports Leadership
Slide 11: 30+ Years of Sterile Liquids Legacy
N I C HE PHA R MA C E U T I CA L C OM PA N Y OP E R AT I ON AL M E TR I C S FI N ANCI A L METR I CS R E VE N U E C A G R EB I T D A CA GR 47 7 1 Product portfolio Production lines WHO-GMP facility 11% 10% 30+ Years of FY21–26 FY21–26 320 120 506 Sterile Liquids Distributors & Intl. jurisdictions Tea
Slide 12: Built to scale – Amanta’s differentiated business model
Built to scale – Amanta’s differentiated business model RM Sourcing Manufacturing Capabilities 3 Channel Distribution Key materials Sourced Manufacturing facility in Gujarat spanning 66,852 sq. mts Robust sales and distribution team with 18.5% strong presence across the globe LVP 4 lines SVP 3 lines
Slide 13: Solutions: A Diverse Product Portfolio (1/2)
Solutions : A Diverse Product Portfolio (1/2) Types of IV Fluids : Notable Formulations : Diluent Product Overview : Dextrose, Normal Saline, Combination Of Ciprofloxacin, Metronidazole, Ofloxacin, • Plain Water for Injection (WFI) Dextrose Normal Saline, Ringer Lactate, Paracetamol, Fluconazole. •
Slide 14: Solutions: A Diverse Product Portfolio (2/2)
Solutions : A Diverse Product Portfolio (2/2) Applications : Applications : Product Types : Administered through nebulisers for the treatment Treatment for Infections, Glaucoma, of lungs affected by Asthma or Bronchiectasis OTC Eye Lubricants Inflammation. Wound Cleaning Solutions Dosage Form : Dosa
Slide 15: Core Competitive Advantages Driving Success
Core Competitive Advantages PR ODU CTS & MAR KE TS D I S T RI BU T I ON Driving Success Well-established Wide Domestic & Pharma Manufacturer Global Network 47 Products Six therapeutic segments and container systems. 47 Pan-India network of 320 distributors, 96 sales staff, and 120 Countries products
Slide 16: Differentiated Manufacturing Technologies to Market End Product
Differentiated Manufacturing Technologies to Market End Product First to bring ISBM technology to India TE CH N OL OG Y 01 TE CH N OL OG Y 02 SUPPORT SYSTEM Aseptic Blow Injection Stretch- F&D Capability Fill Seal (ABFS) Blow Moulding (ISBM) Technology Technology FFS (Form-Fill-Seal) used for IV flu
Slide 17: Excellent Manufacturing Facilities
Excellent Manufacturing Facilities Location: Certifications & Compliance: Production Capabilities: Block No: 872B, 873A, 874, 876 • ISO 9001:2015, ISO 13485:2016, ISO 14001:2015, ISO • Injections and 877 village Hariyala, District 45001:2018, WHO-GMP certified. • Sterile Liquids Kheda Gujarat, India
Slide 18: Sweating the assets to peak capacity
Sweating the assets to peak capacity Utilization % across each Parenteral Capex to drive future growth 130 91 90 73 83 99 98 89 94 91 93 97 93 25 FY23 FY24 FY25 FY26 12 10 6 LVP SVP Steriport Capex (INR Cr) FY26 Installed capacity FY23 FY24 FY25 FY26P FY27P (Units in crs) LVP (excluding SteriPort) 5
Slide 19: Increased Focus on exports – Driving higher margins
Increased Focus on exports – Driving higher margins 32% of revenue 68% of revenue Export markets 21 countries as of Fiscal 2025. Sales focus Domestic branded generics sold under proprietary brand names. Product range • LVP Pack Solutions: IV solutions, anti-fungal, and anti-protozoal formulations. •
Slide 20: De-leveraging in overdrive: Debt-to-Equity ratio reduced
De-leveraging in overdrive: Debt-to-Equity ratio reduced by over 70% since FY23 • Reduced total borrowings by over INR 30 Cr, primarily through the full repayment of all outstanding Non-Convertible Debentures (NCDs). (In Times) (In Times) Debt Service Coverage Ratio Debt to Equity Ratio 1.19 0.76 0.
Slide 21: Leadership: The Board Of Directors
Leadership: The Board Of Directors Mr. Bhavesh Patel Mr. Pratik Gandhi Mr. Nimesh Patel Chairman and Managing Director Non-Executive Director Non-Executive Director 30+ Years Of Experience 10+ Years Of Experience 3+ Years Of Experience Bhavesh Patel is the Chairman and Pratik Gandhi is the Non-Execu
Slide 22: Leadership: The Board Of Directors
Leadership: The Board Of Directors Ms. Anjali Choksi Mr. Kshitij Patel Mr. Nitin Jain Independent Director Independent Director Independent Director 15+ Years Of Experience 25+ Years Of Experience 20+ Years Of Experience Anjali Choksi is an Independent Director of Kshitij Patel is the Independent an
Slide 23: Annual Performance
SECTION 02 Annual Performance FY23 – FY26 Financials
Slide 24: Revenue Breakdown – Annual performance
Revenue Breakdown – Annual performance (Figures in Rs. crs) Revenue from FY26 FY25 FY24 FY23 operations Revenue from contract with customers : Sale of products 282 267 272 253 Sale of services 3 5 6 5 Sub- total 284 272 278 258 Other operating revenue : Scrap sales 2 1 1 1 Export incentives 2 1 0 1
Slide 25: Profit and Loss Statement
Profit and Loss Statement (Figures in Rs. crs) Particulars FY26 FY25 FY24 FY23 Revenues 288 275 280 259 Other Income 3 1 1 4 Total Income 291 276 282 263 Cost of materials consumed 97 101 86 101 Purchases of stock-in-trade 11 12 2 1 Changes in inventories of finished goods, work-in-process and stock
Slide 26: Balance Sheet
Balance Sheet (Figures in Rs. crs) Assets FY26 FY25 FY24 FY23 Equities & Liabilities FY26 FY25 FY24 FY23 Non-Current Assets Equity share capital 39 29 27 27 Property, plant and equipment 197 208 223 229 Other Equity 181 68 40 36 Capital work-in-progress 82 7 - - Net Worth 220 96 66 63 Right-of-use a
Slide 27: Cash Flow Statement
Cash Flow Statement (Figures in Rs. crs) Particulars FY26 FY25 FY24 FY23 Cashflow from Operating Activities 48 47 58 43 Cashflow from Investing Activities (94) (25) (10) (7) Cashflow from Financing Activities 126 (24) (46) (42) Cash and Cash Equivalents as at end of period/Year 81 0.2 1.5 0.1 26
Slide 28: Annexure: Our Product Categories
Performance Annual Business Company Annexure SECTION 05 Annexure Our Product Categories IN THI S SECTION IV fluids Formulations Diluents & injectables Ophthalmic Respiratory Irrigation Glossary
Slide 29: Fluid Therapy - (IV Fluid)
Fluid Therapy - (IV Fluid) Types of IV Fluids : • Dextrose • Normal Saline • Combination Of Dextrose Normal Saline • Ringer Lactate • Electrolytes Packaging Of Product : • Single Port container • Two Port container Fill Volume Options : • 100ml • 250ml • 500ml • 1000ml Innovative Technology : • Ster
Slide 30: Formulations
Formulations Product Focus : Fill Volume Range : • Injectables • 2ml to 100ml Therapeutic Products • Ophthalmic Segments • Respiratory Anti - fungal Fluconazole Technology : • Aseptic Blow-Fill- Seal (ABFS) & Notable Formulations: Injection Stretch Blow Moulding Anti – Pyretic Paracetamol (ISBM) tec
Slide 31: Diluents & Injectables
Diluents & Injectables Key Products : Pack Sizes : • Lidocaine • Offered in 5 ml & 10ml • Potassium Chloride Products : • Magnesium Sulphate • Sterile Water forInjection (WFI) • Calcium Chloride • Normal Saline WFI • Calcium Gluconate Injectables Portfolio Diluents Overview 30
Slide 32: Ophthalmic
Ophthalmic Dosage Form : Therapeutic Product • 5ml & 10ml segments Ciprofloxacin Ophthalmic Solution U.S.P. Ophthalmic (FFS) (0.3 % w/v) Applications : Timolol Maleate Eye Drops B.P.(0.5 % w/v & Ophthalmic (FFS) • Including treatment for Infections, 0.25 % w/v) Applications: Packaging Options: Glauc
Slide 33: Respiratory Solutions
Respiratory Solutions Dosage Form : • Available in 2.5ml Applications : • Administered through nebulizers for the treatment of lungs affected by Asthma or Bronchiectasis. Key Product : • Budesonide Respiratory Suspension • Salbutamol Respiratory Solution • Salbutamol & Ipratropium Bromide Respirator
Slide 34: Irrigation Solutions
Irrigation Solutions Product Types : • OTC Eye Lubricants • Wound Cleaning Solutions Dosage Forms : • Available in 5ml, 10 ml & 20 ml Product : • Sodium Chloride Eye Wash • Wound Cleaning 33
Slide 35: Glossary
Glossary LVP: Large Volume Parenteral SVP: Small Volume Parenteral ABFS: Aseptic Blow Fill Seal ISBM: Injection Stretch-Blow Moulding WFI: Water For Injection SWFI: Sterile Water For Injection WHO-GMP: WHO - Good Manufacturing Practices PICs: Pharmaceutical Inspection Co-operation Scheme ISO: Intern
Slide 36: Investor Relations
Investor Relations Go India Advisors Amanta Healthcare Ltd. Name: Ms. Soumya Chhajed 8th Floor, Shaligram Corporates, Tel: +91-8619707750 C. J. Marg, Ambli, Ahmedabad 380058 Gujarat, India. Email:soumya@goindiaadvisors.com Telephone: 079 6777 7600 Name: Mr. Bobby Ninan Email Id: cs@amanta.co.in Tel: